Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 2/20 | 0.41 |
| ▸ | MC3R | P41968 | 2/20 | 0.41 |
| ▸ | MC1R | Q01726 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26605025 | 1.00 | BDKRB2 (0.54) | BDKRB2CTSLCTSBCTSKAGTR2 | |
| SCHEMBL15798198 | 1.00 | BDKRB2 (0.54) | BDKRB2CTSLCTSBCTSKAGTR2 | |
| SCHEMBL2316672 | 1.00 | BDKRB2 (0.54) | BDKRB2CTSLCTSBCTSKAGTR2 | |
| SCHEMBL1162325 | 0.88 | BDKRB2 (0.43) | BDKRB2MC4RMC3RMC1REPHX2 | |
| SCHEMBL29385583 | 0.85 | BDKRB2 (0.51) | BDKRB2CTSLCTSBCTSKAGTR2 | |
| SCHEMBL28590950 | 0.84 | ALDH1A1 (0.41) | BDKRB2SPHK2ALDH1A1 | |
| SCHEMBL71548 | 0.84 | ABCB1 (0.58) | BDKRB2ABCB1 | |
| SCHEMBL30421047 | 0.84 | ABCB1 (0.58) | BDKRB2ABCB1 | |
| SCHEMBL3855580 | 0.84 | ABCB1 (0.58) | BDKRB2ABCB1 | |
| SCHEMBL28995867 | 0.84 | ABCB1 (0.58) | BDKRB2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161656-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230078839-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KHORA SPV 1, LLC | 2023-03-16 | — | — | US | disclosed |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | KINNATE BIOPHARMA INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-9382258-B2 | Agents for treating pain and uses thereof | ABBVIE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2931727-A1 | DIAZEPINE DERIVATIVES USEFUL AS CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | Abbvie Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150225409-A1 | AGENTS FOR TREATING PAIN AND USES THEREOF | ABBVIE INC. | 2015-08-13 | — | — | US | disclosed |
| US-9029361-B2 | Agents for treating pain and uses thereof | ABBVIE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2014093337-A1 | DIAZEPINE DERIVATIVES USEFUL AS CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | ABBVIE, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140171423-A1 | AGENTS FOR TREATING PAIN AND USES THEREOF | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-1926708-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | Decode Chemistry, Inc. (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007040682-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2007-04-12 | — | — | WO | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | BDKRB2 81/4885CTSL 612/4885CTSB 436/4885 |
| US-20140171423-A1 | AGENTS FOR TREATING PAIN AND USES THEREOF | ACHE, MPO, CALCA | BDKRB2 195/4885CTSL 1283/4885CTSB 454/4885 |
| US-20150225409-A1 | AGENTS FOR TREATING PAIN AND USES THEREOF | ACHE, MPO, CALCA | BDKRB2 195/4885CTSL 1283/4885CTSB 454/4885 |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | BDKRB2 715/4885CTSL 1575/4885CTSB 1207/4885 |
| US-20230078839-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | BDKRB2 715/4885CTSL 1575/4885CTSB 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.